Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer

Citation
At. Schroen et al., Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer, CHEST, 118(1), 2000, pp. 129-137
Citations number
23
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
CHEST
ISSN journal
00123692 → ACNP
Volume
118
Issue
1
Year of publication
2000
Pages
129 - 137
Database
ISI
SICI code
0012-3692(200007)118:1<129:BAPATS>2.0.ZU;2-Y
Abstract
Study objectives: The physicians who initially evaluate patients with non-s mall cell lung cancer (NSCLC) strongly impact the course of therapy. Their beliefs in treatment and prognosis may contribute to practices of variable quality and appropriateness. We sought to better describe beliefs among pul monologists and thoracic surgeons who were selected for guiding early thera py and referrals in patients with NSCLC, Design: Mail questionnaire focusing on survival estimates, treatment percep tions, and referral patterns, Participants:Twelve hundred pulmonologists and 800 thoracic surgeons who we re clinically active members of the American College of Chest Physicians, Measurements and results: Response rates of 50% for pulmonologists and 52% for thoracic surgeons were obtained after two mailings. Five-year survival estimates for patients with resected stage I NSCLC revealed that 30% of res pondents overestimated survival rates and 18% underestimated survival rates . The underestimation of survival rate was found among more respondents who are practicing pulmonology than thoracic surgery (22% vs 0.10%, respective ly), who were trained before 1980 than after 1980 (29% vs 0.10%, respective ly), and who were seeing < 10 lung cancer patients annually than those who were seeing > 25 (31% vs 0.14%, respectively). Beliefs in the survival bene fit of adjuvant chemotherapy or of radiation in stage I-IIIA disease divide d respondents within both specialties, Chemotherapy plus radiation vs radia tion alone in unresectable stage IIIA-B NSCLC was viewed as benefitting sur vival less often by physicians seeing < 10 lung: cancer patients annually r ather than > 25 (57% vs 0.77%, respectively) and by physicians underestimat ing rather than correctly estimating survival in early-stage disease (58% v s 0.72%, respectively). Chemotherapy was believed to confer survival benefi ts in patients with stage IV disease by one third of respondents, Conclusions: Certain physician characteristics, particularly the length of time since training and NSCLC patient volume, are associated with beliefs n ot conclusively supported in the medical literature or with opinions incons istent, within and between specialties.